Eli Lilly, the maker of Zepbound and Mounjaro, faces stiff price competition in the coming year, HSBC says.

Eli Lilly's stock price is based on growth rates that might fall short.

Eli Lilly (LLY) stock drops as HSBC downgrades the company warning that weight-loss drugmaker could be “priced to perfection.

With short-term returns turning negative, analysts are reassessing Lilly's high valuation, reminding the market that even dominant corporations are susceptible to sharp..

Eli Lilly (NYSE:LLY) stock is down 5% in Tuesday afternoon trading, with shares falling to $937 from a prior close of $989.12. The move adds to a rough stretch for the stock, which is now down 13% ...

Eli Lilly's stock is down this year, and its high valuation may be a big reason why.

Eli Lilly has been a growth beast in recent years, but its valuation has gotten fairly high along the way.

HSBC analysts just slashed their recommendation on the world's most valuable pharmaceutical company, Eli Lilly, signaling a potential cooling period for the red-hot obesity drug trade that has come to ...

Eli Lilly (LLY) retatrutide succeeds in Phase 3 trial, cutting blood sugar by 2% and achieving 16.8% weight loss—highest seen ...